127 related articles for article (PubMed ID: 10037002)
1. Detection of minimal residual disease: methods and relationship to outcome in T-lineage acute lymphoblastic leukemia.
Dibenedetto SP; Lo Nigro L; Di Cataldo A; Schilirò G
Leuk Lymphoma; 1998 Dec; 32(1-2):65-75. PubMed ID: 10037002
[TBL] [Abstract][Full Text] [Related]
2. tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease.
Breit TM; Beishuizen A; Ludwig WD; Mol EJ; Adriaansen HJ; van Wering ER; van Dongen JJ
Leukemia; 1993 Dec; 7(12):2004-11. PubMed ID: 8255100
[TBL] [Abstract][Full Text] [Related]
3. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.
Pongers-Willemse MJ; Seriu T; Stolz F; d'Aniello E; Gameiro P; Pisa P; Gonzalez M; Bartram CR; Panzer-Grümayer ER; Biondi A; San Miguel JF; van Dongen JJ
Leukemia; 1999 Jan; 13(1):110-8. PubMed ID: 10049045
[TBL] [Abstract][Full Text] [Related]
4. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
Dibenedetto SP; Lo Nigro L; Mayer SP; Rovera G; Schilirò G
Blood; 1997 Aug; 90(3):1226-32. PubMed ID: 9242556
[TBL] [Abstract][Full Text] [Related]
5. PCR-heteroduplex analysis of TCR gamma, delta and TAL-1 deletions in T-acute lymphoblastic leukemias: implications in the detection of minimal residual disease.
Nirmala K; Rajalekshmy KR; Raman SG; Shanta V; Rajkumar T
Leuk Res; 2002 Apr; 26(4):335-43. PubMed ID: 11839375
[TBL] [Abstract][Full Text] [Related]
6. [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia].
Wang L; Zhang LP; Li ZG; Cheng YF; Tian KG; Lu AD
Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):170-3. PubMed ID: 15833185
[TBL] [Abstract][Full Text] [Related]
7. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
Pongers-Willemse MJ; Verhagen OJ; Tibbe GJ; Wijkhuijs AJ; de Haas V; Roovers E; van der Schoot CE; van Dongen JJ
Leukemia; 1998 Dec; 12(12):2006-14. PubMed ID: 9844931
[TBL] [Abstract][Full Text] [Related]
8. Clonal T-cell receptor gamma and delta gene rearrangements in T-cell acute lymphoblastic leukemia at diagnosis: predictor of prognosis and response to chemotherapy.
Kode J; Dudhal N; Banavali S; Advani S; Chiplunkar S
Leuk Lymphoma; 2004 Jan; 45(1):125-33. PubMed ID: 15061208
[TBL] [Abstract][Full Text] [Related]
9. Quantification of minimal residual disease in T-lineage acute lymphoblastic leukemia with the TAL-1 deletion using a standardized real-time PCR assay.
Chen X; Pan Q; Stow P; Behm FG; Goorha R; Pui CH; Neale GA
Leukemia; 2001 Jan; 15(1):166-70. PubMed ID: 11243385
[TBL] [Abstract][Full Text] [Related]
10. Extensive junctional diversity of gamma delta T-cell receptors expressed by T-cell acute lymphoblastic leukemias: implications for the detection of minimal residual disease.
Breit TM; Wolvers-Tettero IL; Hählen K; van Wering ER; van Dongen JJ
Leukemia; 1991 Dec; 5(12):1076-86. PubMed ID: 1837811
[TBL] [Abstract][Full Text] [Related]
11. Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia.
Brüggemann M; van der Velden VH; Raff T; Droese J; Ritgen M; Pott C; Wijkhuijs AJ; Gökbuget N; Hoelzer D; van Wering ER; van Dongen JJ; Kneba M
Leukemia; 2004 Apr; 18(4):709-19. PubMed ID: 14961040
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a quantitative polymerase chain reaction assay to evaluate minimal residual disease for T-cell acute lymphoblastic leukemia and follicular lymphoma.
Hosler GA; Bash RO; Bai X; Jain V; Scheuermann RH
Am J Pathol; 1999 Apr; 154(4):1023-35. PubMed ID: 10233841
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
[TBL] [Abstract][Full Text] [Related]
14. Detection of minimal residual disease in T-cell acute lymphoblastic leukemia using polymerase chain reaction predicts impending relapse.
Neale GA; Menarguez J; Kitchingman GR; Fitzgerald TJ; Koehler M; Mirro J; Goorha RM
Blood; 1991 Aug; 78(3):739-47. PubMed ID: 1859886
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of minimal residual disease in childhood acute lymphoblastic leukemia patients by polymerase chain reaction analysis of multiple clone-specific or malignancy-specific gene markers.
Kuang S; Gu L; Dong S; Cao Q; Xu C; Huang W; Su XY; Huang QH; Xie JX; Chen SJ; Chen Z
Cancer Genet Cytogenet; 1996 Jun; 88(2):110-7. PubMed ID: 8640718
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
[TBL] [Abstract][Full Text] [Related]
18. Molecular evidence for minimal residual bone marrow disease in children with 'isolated' extra-medullary relapse of T-cell acute lymphoblastic leukemia.
Neale GA; Pui CH; Mahmoud HH; Mirro J; Crist WM; Rivera GK; Goorha RM
Leukemia; 1994 May; 8(5):768-75. PubMed ID: 8182934
[TBL] [Abstract][Full Text] [Related]
19. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology.
Nakao M; Janssen JW; Flohr T; Bartram CR
Cancer Res; 2000 Jun; 60(12):3281-9. PubMed ID: 10866322
[TBL] [Abstract][Full Text] [Related]
20. Detection of minimal residual disease by PCR in childhood T-cell acute lymphoblastic leukemia with TAL1 gene rearrangement: a preliminary report.
Kikuchi A; Hanada R; Yamamoto K; Hayashi Y
Med Pediatr Oncol; 1999 Feb; 32(2):148. PubMed ID: 9950206
[No Abstract] [Full Text] [Related]
[Next] [New Search]
